Advertisement

Tumor Biology

, Volume 37, Issue 10, pp 13279–13286 | Cite as

The inflammatory microenvironment in epithelial ovarian cancer: a role for TLR4 and MyD88 and related proteins

  • Zheng Li
  • Matthew S. Block
  • Robert A. Vierkant
  • Zachary C. Fogarty
  • Stacey J. Winham
  • Daniel W. Visscher
  • Kimberly R. Kalli
  • Chen Wang
  • Ellen L. Goode
Original Article

Abstract

The tumor-associated inflammatory microenvironment may play a pivotal role in epithelial ovarian cancer (EOC) carcinogenesis and outcomes, but a detailed profile in patient-derived tumors is needed. Here, we investigated the expression of TLR4- and MyD88-associated markers in tumors from over 500 EOC patients using immunohistochemical staining. We demonstrate that high expression of TLR4 and MyD88 predicts poorer overall survival in patients with EOC; most likely, this is due to their association with serous histology and features of high tumor burden and aggressiveness, including stage, grade, and ascites at surgery. Combined TLR4 and MyD88 expression appears to serve as an independent risk factor for shortened survival time, even after covariate adjustment (both moderate HR 1.1 [95 % CI 0.7–1.8], both strong HR 2.1 [95 % CI 1.1–3.8], both weak as referent; p = 0.027). We reveal that in EOC tissues with elevated expression of both TLR4 and MyD88 and activated NF-κB signaling pathway, expression of hsp60, hsp70, beta 2 defensin, and HMGB1 are also enriched. In total, these results suggest that activation of TLR4/MyD88/NF-κB signaling by endogenous ligands may contribute to an inflammatory microenvironment that drives a more aggressive phenotype with poorer clinical outcome in EOC patients.

Keywords

Epithelial ovarian cancer Toll-like receptor four (TLR4) Myeloid differentiation primary response gene eighty-eight (MyD88) Endogenous ligands NF-κB signaling pathway 

Notes

Acknowledgments

This work was supported by the Mayo Clinic SPORE in Ovarian Cancer, P50 CA136393, and R01 CA122443.

Compliance with ethical standards

We declare that all experiments were performed in accordance with the current law of USA. The study was approved by the Institutional Review Board (IRB) of Mayo Clinic in Rochester. Patients provided written informed consent and permission for active follow-up.

Conflicts of interest

The authors declare that they have no conflict of interest

Supplementary material

13277_2016_5163_MOESM1_ESM.xlsx (54 kb)
ESM 1 (XLSX 53 kb)
13277_2016_5163_Fig3_ESM.gif (348 kb)
Supplemental Figure 1

Representative images for endogenous ligands, TLR4, and MyD88 Scoring was based on the intensities of nuclear and cytoplasmic staining in the majority of cells. In order to conserve figure space, markers are shown grouped by the scoring scheme used in final analyses; in some instances, this represents combination of score categories: none/weak v moderate/strong (hsp60); none/weak v moderate (gp96, beta 2 defensin); none v weak/moderate (fibrinogen, heparan sulfate); none v weak v moderate (hsp70, HMGB1); and none/weak v moderate v strong (TLR4 and MyD88). (GIF 347 kb)

13277_2016_5163_MOESM2_ESM.tif (91.1 mb)
High Resolution Image (TIFF 93301 kb)
13277_2016_5163_Fig4_ESM.gif (316 kb)
Supplemental Figure 2

Representative images for NF-κB signaling pathway and target gene In order to conserve figure space, markers are shown grouped by the scoring scheme used in final analyses; in some instances, this represents combination of score categories: none v weak v moderate intensity of nuclear and cytoplasmic staining in the majority of cells (IKKβ, IκBα, p50, MMP9); none v weak/moderate intensity of nuclear and cytoplasmic staining in the majority of cells (phospho-IκBα); and <10 % v > =10 % of positive cells in nuclei (phospho-p65). (GIF 316 kb)

13277_2016_5163_MOESM3_ESM.tif (457 kb)
High Resolution Image (TIFF 457 kb)

References

  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.CrossRefPubMedGoogle Scholar
  2. 2.
    Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 2011;61:183–203.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351:2519–29.CrossRefPubMedGoogle Scholar
  4. 4.
    De Nardo D. Toll-like receptors: activation, signalling and transcriptional modulation. Cytokine. 2015;74(2):181–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Muccioli M, Benencia F. Toll-like receptors in ovarian cancer as targets for immunotherapies. Front Immunol. 2014;5:341.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Kelly MG, Alvero AB, Chen R, Silasi DA, Abrahams VM, Chan S, et al. TlR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res. 2006;66:3859–68.CrossRefPubMedGoogle Scholar
  7. 7.
    Szajnik M, Szczepanski MJ, Czystowska M, Elishaev E, Mandapathil M, Nowak-Markwitz E, et al. TlR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer. Oncogene. 2009;28:4353–63.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Kim KH, Jo MS, Suh DS, Yoon MS, Shin DH, Lee JH, et al. Expression and significance of the TLR4/Myd88 signaling pathway in ovarian epithelial cancers. World J Surg Oncol. 2012;10:193.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Zhu Y, Huang JM, Zhang GN, Zha X, Deng BF. Prognostic significance of Myd88 expression by human epithelial ovarian carcinoma cells. J Transl Med. 2012;10:77.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Luo XZ, He QZ, Wang K. Expression of toll-like receptor 4 in ovarian serous adenocarcinoma and correlation with clinical stage and pathological grade. Int J Clin Exp Med. 2015;8:14323–7.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Yu L, Wang L, Chen S. Endogenous toll-like receptor ligands and their biological significance. J Cell Mol Med. 2010;14:2592–603.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Kobel M, Kalloger SE, Lee S, Duggan MA, Kelemen LE, Prentice L, et al. Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium. Cancer Epidemiol Biomark Prev. 2013;22:1677–86.CrossRefGoogle Scholar
  13. 13.
    Karin M, Greten FR. Nf-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5:749–59.CrossRefPubMedGoogle Scholar
  14. 14.
    Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883–99.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.CrossRefPubMedGoogle Scholar
  16. 16.
    Lavoue V, Thedrez A, Leveque J, Foucher F, Henno S, Jauffret V, et al. Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer. J Transl Med. 2013;11:147.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Maccio A, Madeddu C. Inflammation and ovarian cancer. Cytokine. 2012;58:133–47.CrossRefPubMedGoogle Scholar
  18. 18.
    Rakoff-Nahoum S, Medzhitov R. Toll-like receptors and cancer. Nat Rev Cancer. 2009;9:57–63.CrossRefPubMedGoogle Scholar
  19. 19.
    Zhou M, McFarland-Mancini MM, Funk HM, Husseinzadeh N, Mounajjed T, Drew AF. Toll-like receptor expression in normal ovary and ovarian tumors. Cancer Immunol Immunother. 2009;58:1375–85.CrossRefPubMedGoogle Scholar
  20. 20.
    Wang AC, Ma YB, FX W, Ma ZF, Liu NF, Gao R, et al. TLR4 induces tumor growth and inhibits paclitaxel activity in MyD88-positive human ovarian carcinoma. Oncol Lett. 2014;7:871–7.PubMedGoogle Scholar
  21. 21.
    d’Adhemar CJ, Spillane CD, Gallagher MF, Bates M, Costello KM, Barry-O’Crowley J, et al. The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer. PLoS One. 2014;9:e100816.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Tsan MF. Toll-like receptors, inflammation and cancer. Semin Cancer Biol. 2006;16:32–7.CrossRefPubMedGoogle Scholar
  23. 23.
    Sato Y, Goto Y, Narita N, Hoon DS. Cancer cells expressing toll-like receptors and the tumor microenvironment. Cancer Microenviron. 2009;2(Suppl 1):205–14.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Guo RX, Qiao YH, Zhou Y, Li LX, Shi HR, Chen KS. Increased staining for phosphorylated AKT and nuclear factor-kappaB p65 and their relationship with prognosis in epithelial ovarian cancer. Pathol Int. 2008;58:749–56.CrossRefPubMedGoogle Scholar
  25. 25.
    Darb-Esfahani S, Sinn BV, Weichert W, Budczies J, Lehmann A, Noske A, et al. Expression of classical NF-kappaB pathway effectors in human ovarian carcinoma. Histopathology. 2010;56:727–39.CrossRefPubMedGoogle Scholar
  26. 26.
    Annunziata CM, Stavnes HT, Kleinberg L, Berner A, Hernandez LF, Birrer MJ, et al. Nuclear factor kappab transcription factors are coexpressed and convey a poor outcome in ovarian cancer. Cancer. 2010;116:3276–84.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Zheng Li
    • 1
    • 2
  • Matthew S. Block
    • 3
  • Robert A. Vierkant
    • 1
  • Zachary C. Fogarty
    • 1
  • Stacey J. Winham
    • 1
  • Daniel W. Visscher
    • 4
  • Kimberly R. Kalli
    • 3
  • Chen Wang
    • 1
  • Ellen L. Goode
    • 1
  1. 1.Department of Health Sciences ResearchMayo ClinicRochesterUSA
  2. 2.Department of Gynecologic OncologyThe Third Affiliated Hospital of Kunming Medical University (Yunnan Tumor Hospital)KunmingChina
  3. 3.Department of Medical OncologyMayo ClinicRochesterUSA
  4. 4.Department of Laboratory MedicineMayo ClinicRochesterUSA

Personalised recommendations